Form 4: Viracta Therapeutics Officer Acquires 120,000 Stock Options

Darrel P. Cohen, Chief Medical Officer of Viracta Therapeutics, acquired 120,000 stock options on March 12, 2024, at an exercise price of $0.985.

Summary

• On March 12, 2024, Darrel P. Cohen, the Chief Medical Officer of Viracta Therapeutics, acquired 120,000 stock options.
• The exercise price for these options is $0.985.
• The options vest monthly, with 1/48th of the total shares vesting each month starting from January 1, 2024, subject to continued service.
• The options expire on March 12, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction (stock option grant) which is generally viewed as a positive sign of aligning management interests with shareholders. It's a neutral to slightly positive event.

Positives

• The acquisition of stock options by a key officer aligns their interests with the company's success.

Future Outlook

The document does not contain any specific forward-looking statements or guidance.

Industry Context

This is a standard Form 4 filing, reflecting a common practice of granting stock options to company officers as part of their compensation package. It's typical for biotech companies to use equity-based compensation to attract and retain talent.

Comparison to Industry Standards

• Stock option grants are a common component of executive compensation packages in the biotechnology industry.
• The vesting schedule of 1/48th per month is a fairly standard vesting schedule.
• The exercise price is inline with the current stock price.

Stakeholder Impact

• The stock option grant aligns the interests of the Chief Medical Officer with those of the shareholders.

Key Dates

Keywords

stock options, Viracta Therapeutics, Form 4, officer, acquisition, Cohen, VIRX